Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 10:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 12,238 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Diseases Clear all

Conditions: Multiple Myeloma
Interventions: Survivin Vaccine, Autologous Hematopoietic Cell Transplantation, Prevnar 13, Granulocyte-colony Stimulating Factor; Biological · Procedure · Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Sickle Cell Disease
Interventions: Crizanlizumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Months to 100 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 7
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Augusta, Georgia + 3 more

Conditions: Arthroplasty, Replacement, Knee
Interventions: Triathlon PKR; Device
Lead sponsor: Stryker Orthopaedics; Industry
Eligibility: 21 Years to 75 Years
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2023
U.S. locations: 6
States / cities: Jacksonville, Florida • Egg Harbor, New Jersey • Buffalo, New York + 3 more

Conditions: Onychomycosis
Interventions: ME1111 solution, Vehicle Solution; Drug
Lead sponsor: Meiji Seika Pharma Co., Ltd.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 2
States / cities: Austin, Texas • College Station, Texas

Conditions: Osteogenesis Imperfecta (OI)
Interventions: AGA2115, Placebo; Drug · Other
Lead sponsor: Angitia Incorporated Limited; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 9
States / cities: Phoenix, Arizona • New Haven, Connecticut • Wilmington, Delaware + 6 more

Conditions: Multiple Myeloma
Interventions: Elotuzumab (HuLuc63); Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 8
States / cities: Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 5 more

Conditions: Bladder Outlet Obstruction, Multiple Sclerosis, Cauda Equina Syndrome, Enlarged Prostate With Lower Urinary Tract Symptoms, Parkinson Disease, Lower Urinary Tract Symptoms, Detrusor Underactivity, Spinal Cord Injuries
Interventions: Intermittent self-catheterisation; Device
Lead sponsor: ConvaTec Inc.; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: West Orange, New Jersey • Philadelphia, Pennsylvania

Conditions: Diabetes Mellitus, Type 2
Interventions: LY3437943, Dulaglutide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 20 Years to 70 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 4
States / cities: Anaheim, California • Miami, Florida • Lenexa, Kansas + 1 more

Conditions: Multiple Sclerosis
Interventions: placebo, memantine; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 70 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Schizophrenia, Pediatric
Interventions: Lumateperone 42 mg, Lumateperone 28 mg; Drug
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Hollywood, Florida • Atlanta, Georgia • Decatur, Georgia

Conditions: Asthma
Interventions: Budesonide/formoterol (SYMBICORT) pMDI, Budesonide HFA pMDI; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years and older
Enrollment: 558 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 32
States / cities: Anaheim, California • Chula Vista, California • Fresno, California + 29 more

Conditions: Heavy Menstrual Bleeding, Abnormal Uterine Bleeding, Menorrhagia
Interventions: Cerene; Device
Lead sponsor: Channel Medsystems; Industry
Eligibility: 25 Years and older · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: West Orange, New Jersey • Cincinnati, Ohio

Conditions: 22q11 Deletion Syndrome, DiGeorge Syndrome, Trisomy 21, Trisomy 18, Trisomy 13, Monosomy X, Sex Chromosome Abnormalities, Cri-du-Chat Syndrome, Angelman Syndrome, Prader-Willi Syndrome, 1p36 Deletion Syndrome
Interventions: Not listed
Lead sponsor: Natera, Inc.; Industry
Eligibility: 18 Years to 48 Years · Female only
Enrollment: 20,960 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 16
States / cities: San Francisco, California • Camden, New Jersey • Mount Laurel, New Jersey + 10 more

Conditions: Down Syndrome
Interventions: No Intervention; Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Tucson, Arizona • Boston, Massachusetts • Durham, North Carolina

Conditions: Asthma, Coronary Artery Disease, Pulmonary Disease, Chronic Obstructive
Interventions: Regadenoson, Placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 1,009 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 48
States / cities: Montgomery, Alabama • Anaheim, California • Encinitas, California + 43 more

Conditions: Non-Hodgkin's Lymphoma
Interventions: Bendamustine HCl; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 32
States / cities: Birmingham, Alabama • Tucson, Arizona • Berkeley, California + 28 more

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy
Interventions: Immune globulin (human) 10% solution for intravenous administration; Biological
Lead sponsor: Kedrion S.p.A.; Industry
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 6
States / cities: Stamford, Connecticut • Miami, Florida • Pembroke Pines, Florida + 3 more

Conditions: Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions: MK-5160 16 nmol/kg, MK-5160 32 nmol/kg, MK-5160 64 nmol/kg, Glargine 0.4 U/kg, Placebo to Glargine, Placebo to MK-5160, Dextrose, Glargine 0.6 U/kg; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema, Diabetic Macular Edema, Diabetic Retinopathy
Interventions: FYB203 2 mg (0.05 mL of 40 mg/mL); Drug
Lead sponsor: Formycon AG; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 4
States / cities: Campbell, California • Long Beach, California • Redlands, California + 1 more

Conditions: Systemic Lupus Erythematosus
Interventions: Epratuzumab; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 20
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 17 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: Insulin detemir, Insulin NPH, Diet/exercise; Drug · Behavioral
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 10 Years to 18 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 23
States / cities: Tucson, Arizona • Los Angeles, California • Jacksonville, Florida + 19 more

Conditions: Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema
Interventions: pegaptanib sodium injection; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 50 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 4
States / cities: Murrieta, California • Marshalltown, Iowa • West Mifflin, Pennsylvania + 1 more

Conditions: Respiratory Distress Syndrome, Adult
Interventions: Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells, Plasma-Lyte A; Biological
Lead sponsor: Michael A. Matthay; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 6
States / cities: San Francisco, California • Stanford, California • Boston, Massachusetts + 3 more

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: BG00002 (natalizumab), interferon beta-1a, glatiramer acetate; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 19
States / cities: Cullman, Alabama • Phoenix, Arizona • Fort Collins, Colorado + 16 more

Search by objective public record fields.

Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT)

Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study

Triathlon® Partial Knee Replacement (PKR) Outcomes Study

Pharmacokinetics and Safety Study of ME1111 in Moderate to Severe Onychomycosis Patients

Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)

A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies.

GentleCath™ for Men Intermittent Catheter With FeelClean™ Technology

A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)

Memantine for Spasticity in MS Patients

Safety, Tolerability, and Pharmacokinetics of Lumateperone in Pediatric Patients With Schizophrenia or Schizoaffective Disorder

An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma

A Registry to Gather Real World Use Data on the Cerene® Cryotherapy Device

SNP-based Microdeletion and Aneuploidy RegisTry (SMART)

Non-drug Study to Evaluate the Suitability of Neurocognitive Tests and Functioning Scales for the Measurement of Cognitive and Functioning Changes in Children With Down Syndrome

A Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease

Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab

A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002)

Ocular Safety and Usability Study for FYB203 PFS

Study of Epratuzumab in Systemic Lupus Erythematosus

A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin

Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium

Human Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (START)

Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis